Saturday 17 October 2026
Export HIND’s income statement to Excel — free account
Vyome Holdings, Inc.
HIND Healthcare Biotechnology
In the quarter to June 2026, revenue fell 46.0%, EPS grew 100.0% and free cash flow fell 195.0%, each against the same quarter a year earlier.
1.87
0.04
−2.09%
Follow HIND
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 23.25 | 94.13 | 116.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.11) | (5.03) | (10.02) | (16.70) | |
P/B ratio |
3.65 | 1.98 | 1.79 | 2.06 | |
Price to Tangible BV |
3.96 | 2.16 | 1.86 | 2.16 | |
EV/Sales |
(6.18) | 47.56 | 120.06 | 153.78 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.38) | (4.06) | (3.68) | (3.58) | |
EV/FCF |
(9.39) | (4.06) | (3.68) | (3.58) | |
Quick Ratio |
1.84 | 1.82 | 4.10 | 4.23 | |
Current Ratio |
1.94 | 1.99 | 4.27 | 4.37 | |
Net Debt/EBITDA |
0.67 | 3.68 | 7.80 | 9.17 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
(0.55) | 0.08 | 0.02 | 0.01 | |
Operating CF/Net income |
0.21 | 1.21 | 1.49 | 1.32 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(334.93) | (136.88) | (403.54) | (261.39) | |
Research and Development Expense of Revenue |
114.74% | 1,033.61% | 2,108.86% | 1,876.67% | |
Selling, General and Administrative Expense of Revenue |
2,440.17% | 2,721.86% | 1,511.39% | 1,351.48% | |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
18,710.40% | 281.42% | 112.97% | 40.74% | |
Graham Net Nets |
0.20 | 0.36 | 0.49 | 0.42 | |
Graham Number |
0.00 | 0.00 | 143.04 | 189.27 | |
Earnings Yield |
(33,312.95%) | (141.04%) | 35,190.19% | 71,087.86% | |
Free Cash Flow Yield |
(15.91%) | (50.43%) | (34.63%) | (36.97%) | |
Revenue per Share |
0.01 | 0.02 | 0.00 | 0.00 | |
Operating CF per Share |
(0.64) | (0.68) | (0.21) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.64) | (0.68) | (0.21) | (0.13) | |
Cash per Share |
2.07 | 2.31 | 1.31 | 1.12 | |
Shareholders Equity per Share |
1.42 | 1.74 | 1.20 | 1.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.42 | 1.74 | 1.20 | 1.04 | |
Free Cash Flow |
(1.76) | (1.48) | (1.44) | (0.90) | |
Working Capital |
2.92 | 2.70 | 7.02 | 6.29 | |
Net Current Asset Value |
2.91 | 2.70 | 7.02 | 6.29 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.68 | — | — | — | |
Average Payables |
2.00 | 1.13 | 1.40 | 1.21 | |
Average Assets |
6.33 | 3.94 | 8.33 | 9.10 | |
Average Common Equity |
2.70 | (0.31) | 4.64 | 6.57 |
Columns are period end dates · fundamentals updated 1 Oct 2026